Tharos Ltd.

Lonza Inc.

Universidad De Chile

Pontificia Universidad Catòlica De Chile

Pontifica Universidad Catolica De Chile

Mario Martin Chiong Lay

Dimitri Sclabos Katevas

Raúl R Toro Guerra

Jorge Emilio Jalil Milad

Sergio Alejandro Lavandero González

María Paz Ocaranza Jeraldino

Raul R Toro Guerra

Luis Fernando Michea Acevedo

Raül R Toro Guerra

The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogs, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2. This invention allows the administration of angiotensin-(1-9) or the derivatives thereof in oral form, injectable form, continuous infusion pump, or for increasing its levels in the body by means of the combined treatment with angiotensin-I converting enzyme inhibitors, with angiotensin-II receptor antagonists (ARA II), with Rho kinase inhibitors, with renin inhibitors, with L-type calcium channel antagonists and/or with diuretics.

Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ACE2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation

Organic solvent-free processes for obtaining krill oil compositions are disclosed. The processes include a) cooking krill in a cooker vessel for a time and temperature sufficient to denature the protein content of the krill and cause a first solid krill fraction and first liquid krill fraction to be formed while substantially avoiding emulsification of the first solid and first liquid krill fractions; b) removing the first solid and first liquid krill fractions from the cooker vessel at a temperature of at least about 90&#xb0; C.; c) separating the first solid fraction and the first liquid fraction; and d) obtaining krill oil with neutral enriched from the first liquid fraction, and e) by pressing of first solid fraction to obtain press liquid or a second liquid krill fraction for obtaining krill oil with phospholipids enriched krill oil, the separating and the obtaining steps being carried out without the use of organic solvents.

Solvent-free process for obtaining phospholipids and neutral enriched krill oils

A pharmaceutical composition is provided having an effective amount of angiotensin-(1-9) and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Also provided is a method of using the pharmaceutical composition for inhibiting and/or reducing cardiovascular remodeling.

Pharmaceutical compositions comprising angiotensin-(1-9), derivatives thereof, or a vector expressing ACE2, useful for treating cardiovascular, pulmonary, cerebral, and/or renal remodeling

The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing DHA and EPA poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature&#x2014;without agitation and or grinding; decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid; squeezing the obtained solid to obtain a press liquid and a solid fraction; centrifuging the press liquid to obtain the phospholipids enriched krill oil; centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater.

Solvent-Free Process for Obtaining Phospholipids and Neutral Enriched Krill Oils

Organic solvent-free processes for obtaining krill oil compositions are disclosed. The processes include a) cooking krill in a cooker vessel for a time and at a temperature sufficient to denature the protein content of the krill and cause a first solid krill fraction and a first liquid krill fraction to be formed while substantially avoiding emulsification of the first solid and first liquid krill fractions; b) removing the first solid and first liquid krill fractions from the cooker vessel at a temperature of at least about 90&#xb0; C.; c) separating the first solid fraction and the first liquid fraction; and d) obtaining krill oil with neutral enriched from the first liquid fraction, and e) by pressing of first solid fraction to obtain press liquid or a second liquid krill fraction for obtaining krill oil with phospholipids enriched krill oil, the separating and the obtaining steps being carried out without the use of organic solvents. Krill oil compositions made by the process are also disclosed.

The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing DHA and EPA poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature-without agitation and or grinding; decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid; squeezing the obtained solid to obtain a press liquid and a solid fraction; centrifuging the press liquid to obtain the phospholipids enriched krill oil; centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater.

Growing community of inventors

Santiago, Chile

Mario Martin Chiong Lay